Pamela Walker, Ph.D

A prime opportunity for pharma to raise its strategic game in ESG.

The pharma industry is beginning to perform better with environmental, social, and governance (ESG).

Thriving in the new COVID-19 world requires five key ingredients, which can be leveraged with a transformative approach to digital adoption in the pharma space.

Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.

Dr. Pamela Walker asks, in an increasingly competitive marketplace, with greater understanding of behavioral biases such as loss aversion, how can pharma professionals use loss aversion to propel brands to success?